GlassScriptPhysician profile
Ricardo Ruiz
NPI 1477110336
$8,068.34
in general payments reported to CMS, 2019-2025
22 companies · $4,004 in 2025
The $4,004 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,560 · 2022: $1,051 · 2023: $666 · 2024: $788 · 2025: $4,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,616 · Food and Beverage: $2,269 · Travel and Lodging: $390 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,616.00 |
| Food and Beverage | $2,269.49 |
| Travel and Lodging | $389.92 |
| Education | $182.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,422.62 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $1,056.36 | 2021-2023 | Ocaliva |
| Gilead Sciences, INC. | $693.90 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $512.15 | 2021-2025 | Xifaxan |
| Abbvie INC. | $466.76 | 2021-2022 | |
| Ardelyx, INC. | $374.11 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $329.05 | 2022-2025 | Tremfya |
| Redhill Biopharma INC. | $249.00 | 2021 | |
| Laborie Medical Technologies Corp. | $239.43 | 2022-2023 | |
| Celgene Corporation | $157.25 | 2021-2022 | |
| Orphalan INC | $125.00 | 2024 | Cuvrior |
| Qol Medical, LLC | $78.18 | 2022-2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $67.93 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $61.53 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $59.18 | 2025 | Zenpep |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.95 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $28.73 | 2023 | Stelara |
| Regeneron Pharmaceuticals, INC. | $28.51 | 2022 | |
| Madrigal Pharmaceuticals | $28.05 | 2025 | Rezdiffra |
| Sandoz INC. | $25.00 | 2024 | |
| Ethicon US, LLC | $14.45 | 2021 | |
| Boston Scientific Corporation | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.